New real-world evidence published in Nature Communications is adding to safety comparisons for second-line antihyperglycemic agents in older adults with type 2 diabetes. The study, led by Kim, Bu, Blacketer and colleagues, focuses on elderly patients and evaluates comparative safety outcomes outside controlled trial settings. The work is framed as an effort to translate medication risk profiling into routine clinical decision-making, where comorbidities, polypharmacy, and frailty can alter tolerability. By using observational evidence, the study targets the evidence gaps clinicians face when selecting add-on therapies after initial diabetes treatment. The finding set is likely to influence how clinicians weigh second-line options for elderly patients—particularly where the balance of efficacy and adverse events becomes more complex with age.